Skinvisible (SKVI) Free Cash Flow Growth (3y) (2013 - 2026)
Powered by 
Analysis
Skinvisible (SKVI) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 647.22 Bn | 626.46 Bn | 17.26 Bn | 33.62% |
| 2 | AbbVie | 440.28 Bn | 433.71 Bn | 12.70 Bn | -20.26% |
| 3 | Merck | 364.30 Bn | 357.16 Bn | 12.21 Bn | 17.80% |
| 4 | Novartis Ag | 268.44 Bn | 260.75 Bn | 11.24 Bn | 17.73% |
| 5 | Pfizer | 158.60 Bn | 146.90 Bn | 10.94 Bn | 28.91% |
| 6 | Sanofi | 52.56 Bn | 45.18 Bn | 10.79 Bn | 56.97% |
| 7 | Revolution Medicines | 44.31 Bn | 44.31 Bn | - | - |
| 8 | Incyte | 24.98 Bn | 20.45 Bn | 1.57 Bn | 18.29% |
| 9 | United Therapeutics | 21.16 Bn | 18.49 Bn | 683.80 Mn | 49.44% |
| 10 | Skinvisible | 1.08 Mn | 1.08 Mn | 5,000.00 | 27.74% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 27.74% |
| Mar 31, 2026 | 74.94% |
| Dec 31, 2025 | 26.89% |
| Sep 30, 2025 | 26.33% |
| Jun 30, 2025 | -27.15% |
| Mar 31, 2025 | 8.15% |
| Dec 31, 2024 | -28.26% |
| Sep 30, 2024 | -31.08% |
| Jun 30, 2024 | -29.44% |
| Mar 31, 2024 | 8.63% |
| Dec 31, 2023 | -28.61% |
| Sep 30, 2023 | 40.59% |
| Jun 30, 2023 | -38.63% |
| Mar 31, 2023 | -46.19% |
| Dec 31, 2022 | 33.18% |
| Sep 30, 2022 | -85.99% |
| Jun 30, 2022 | 101.07% |
| Mar 31, 2022 | 4.41% |
| Dec 31, 2021 | 74.96% |
| Sep 30, 2021 | 46.68% |